These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16250839)

  • 1. Phosphodiesterase inhibitors for cognitive enhancement.
    Rose GM; Hopper A; De Vivo M; Tehim A
    Curr Pharm Des; 2005; 11(26):3329-34. PubMed ID: 16250839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
    Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
    Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving memory: a role for phosphodiesterases.
    Blokland A; Schreiber R; Prickaerts J
    Curr Pharm Des; 2006; 12(20):2511-23. PubMed ID: 16842174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit?
    Ghavami A; Hirst WD; Novak TJ
    Drugs R D; 2006; 7(2):63-71. PubMed ID: 16542053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.
    Al-Nema MY; Gaurav A
    Curr Top Med Chem; 2020; 20(26):2404-2421. PubMed ID: 32533817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors say NO to Alzheimer's disease.
    Nabavi SM; Talarek S; Listos J; Nabavi SF; Devi KP; Roberto de Oliveira M; Tewari D; Argüelles S; Mehrzadi S; Hosseinzadeh A; D'onofrio G; Orhan IE; Sureda A; Xu S; Momtaz S; Farzaei MH
    Food Chem Toxicol; 2019 Dec; 134():110822. PubMed ID: 31536753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
    Gulisano W; Tropea MR; Arancio O; Palmeri A; Puzzo D
    Neuropharmacology; 2018 Aug; 138():151-159. PubMed ID: 29885420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Object memory enhancement by combining sub-efficacious doses of specific phosphodiesterase inhibitors.
    Bollen E; Akkerman S; Puzzo D; Gulisano W; Palmeri A; D'Hooge R; Balschun D; Steinbusch HW; Blokland A; Prickaerts J
    Neuropharmacology; 2015 Aug; 95():361-6. PubMed ID: 25896769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
    Jabaris SS; Sumathy H; Girish R; Narayanan S; Sugumar M; Saravana Babu C; Thanikachalam S; Thanikachalam M
    Brain Res; 2015 Oct; 1622():279-91. PubMed ID: 26168894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug targets for cognitive enhancement in neuropsychiatric disorders.
    Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
    Wu Y; Li Z; Huang YY; Wu D; Luo HB
    J Med Chem; 2018 Jul; 61(13):5467-5483. PubMed ID: 29363967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
    Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task.
    Vardigan JD; Converso A; Hutson PH; Uslaner JM
    J Neurogenet; 2011 Dec; 25(4):120-6. PubMed ID: 22070409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatric aspects of phosphodiesterases: An overview.
    Murthy VS; Mangot AG
    Indian J Pharmacol; 2015; 47(6):594-9. PubMed ID: 26729948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Prickaerts J; Heckman PRA; Blokland A
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction.
    Duinen MV; Reneerkens OA; Lambrecht L; Sambeth A; Rutten BP; Os JV; Blokland A; Prickaerts J
    Curr Pharm Des; 2015; 21(26):3813-28. PubMed ID: 26044976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.
    Reneerkens OA; Rutten K; Steinbusch HW; Blokland A; Prickaerts J
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):419-43. PubMed ID: 18709359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PDE4 cAMP-Specific Phosphodiesterases: Targets for Drugs with Antidepressant and Memory-Enhancing Action.
    Bolger GB
    Adv Neurobiol; 2017; 17():63-102. PubMed ID: 28956330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase inhibition in cognitive decline.
    García-Barroso C; Ugarte A; Martínez M; Rico AJ; Lanciego JL; Franco R; Oyarzabal J; Cuadrado-Tejedor M; García-Osta A
    J Alzheimers Dis; 2014; 42 Suppl 4():S561-73. PubMed ID: 25125473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.